Home › Funds › MPM BioImpact LLC › ABVX
MPM BioImpact LLC position in ABVX
ABIVAX SA · Health Care
MPM BioImpact LLC reported holding 336,347 shares of ABVX (ABIVAX SA) in its Q2 2026 13F filing — a position valued at US$44.8M, representing 2.73% of its reported portfolio and ranking #14 among its reported holdings. MPM BioImpact LLC has disclosed ABVX holdings in 3 of the last 3 reported quarters, going back to Q4 2025.
Last updated: 2026-10-24 · Source: SEC EDGAR Form 13F-HR
How MPM BioImpact LLC's ABVX position evolved
MPM BioImpact LLC first disclosed a stake in ABVX in Q4 2025 at 56,316 shares (US$7.6M). The position peaked in Q2 2026 at 336,347 shares, worth US$44.8M. Across 3 filings, MPM BioImpact LLC increased the stake 2 time(s), trimmed it 0 time(s) and left it unchanged 0 time(s). The most recent filing (Q2 2026) shows 336,347 shares valued at US$44.8M — an increase of 229,079 shares quarter over quarter.. Notable position changes include a 90% increase in Q1 2026 (shares rose 20% over the following quarter), a 214% increase in Q2 2026 (shares fell 26% over the following quarter).
Quarter by quarter
| Quarter | Shares | Value | Change |
|---|---|---|---|
| Q4 2025 | 56.32K | $7.59M | New |
| Q1 2026 | 107.27K | $11.94M | Add |
| Q2 2026 | 336.35K | $44.82M | Add |
Dots on the line are colored by change type; missing quarters mean no position was reported.
About ABVX and 13F data
ABVX (ABIVAX SA) is a Health Care company. 72 other funds we track also report a position in ABVX — the largest reported positions include TCG Crossover Management, LLC (US$800.6M), Helikon Investments Ltd (US$371.4M), Darwin Global Management, Ltd. (US$348.2M). Under SEC rules, institutional investment managers with over $100M in assets must file Form 13F within 45 days of each quarter-end, disclosing long positions in US-listed equities. The data excludes short positions, most options and foreign holdings, so treat it as a quarterly snapshot rather than a live position.
Other funds holding ABVX
- TCG Crossover Management, LLC 6.01M sh · $800.60M · Q2 2026
- Helikon Investments Ltd 2.79M sh · $371.41M · Q2 2026
- Darwin Global Management, Ltd. 3.62M sh · $348.22M · Q2 2026
- Vestal Point Capital, LP 2.35M sh · $313.09M · Q2 2026
- Caligan Partners LP 1.56M sh · $207.61M · Q2 2026
- WESTFIELD CAPITAL MANAGEMENT CO LP 1.31M sh · $174.55M · Q2 2026
- RA CAPITAL MANAGEMENT, L.P. 1.13M sh · $150.92M · Q2 2026
- Logos Global Management LP 1.02M sh · $136.46M · Q2 2026
- Octagon Capital Advisors LP 993.00K sh · $132.33M · Q2 2026
- Eversept Partners, LP 913.88K sh · $121.78M · Q2 2026
- Nationale-Nederlanden Powszechne Towarzystwo Emerytalne S.A. 765.33K sh · $101.99M · Q2 2026
- Cormorant Asset Management, LP 675.00K sh · $89.95M · Q2 2026
More on MPM BioImpact LLC
FAQ
How long has MPM BioImpact LLC held ABVX?
MPM BioImpact LLC has disclosed ABVX holdings in 3 of the last 3 reported quarters, going back to Q4 2025.
What is MPM BioImpact LLC's current position in ABVX?
As of Q2 2026, MPM BioImpact LLC holds 336.35K shares of ABVX (ABIVAX SA), valued at $44.82M, representing 2.73% of its reported portfolio and ranking #14.
Has MPM BioImpact LLC been buying or selling ABVX?
In the latest 13F filing (Q2 2026), MPM BioImpact LLC increased its position in ABVX. The position peaked in Q2 2026 at 336.35K shares.
Which other funds hold ABVX?
Other major institutional holders of ABVX include TCG Crossover Management, LLC, Helikon Investments Ltd, Darwin Global Management, Ltd., among 72 funds with disclosed positions.
Where does this data come from?
All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.